Regeneron announces publication of one-year results from PULSAR and PHOTON trials
March 8th 2024Results show Eylea HD extended dosing regimens were non-inferior to aflibercept 2 mg injection (Eylea) for both the treatment of wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).
Viewing the 2024 Solar Eclipse safely
March 7th 2024Jeff Todd, president and CEO of Prevent Blindness, and astrophotographer Jon Carmichael sat down with David Hutton of Ophthalmology Times to talk about how ophthalmologists can help make sure patients are viewing the eclipse safely as well as proper ways to view/photograph the event without damaging your eyes or equipment.
Ophthalmology pioneer Walter J. Stark, MD, passes away at 81
March 3rd 2024After completing his residency at the Wilmer Eye Institute and a fellowship at NIH, Walter J. Stark, MD, returned to Wilmer for a 40-year career as a surgeon, teacher, researcher, and Boone Pickens Professor of Ophthalmology and chief of the Cornea Division.
AGS 2024: Bridging the language barrier in eye care
March 2nd 2024David Sola-Del Valle, MD, sat down with David Hutton of Ophthalmology Times to discuss his talk at the annual American Glaucoma Society meeting held in Huntington Beach, about the importance of bridging the language barrier in patients who may not be fluent in English.
AGS 2024: Tips for implementing telehealth into ophthalmology
March 1st 2024April Maa, MD, sat down with David Hutton of Ophthalmology Times to discuss her presentation at the annual American Glaucoma Society meeting held in Huntington Beach, about tips and tricks for implementing telehealth into ophthalmology.
AGS 2024: Laser refractive surgery in high-risk glaucoma suspects
March 1st 2024Michael Greenwood, MD, discusses the safety of laser refractive surgery for patients at high risk for glaucoma, focusing on the need for thorough pre-surgery assessment, careful monitoring of eye pressure during and after the procedure, and awareness of prolonged steroid use following PRK.
AGS 2024: Travoprost intraocular implant safe and effective in phakic eyes
February 29th 2024Steven R. Sarkisian, MD, sat down with David Hutton of Ophthalmology Times to discuss his poster about the Travoprost intraocular implant in phakic eyes from the American Glaucoma Society meeting held in Huntington Beach
AGS 2024: Travoprost intraocular implant in OAG and OHT subjects
February 29th 2024I. Paul Singh, MD, sat down with David Hutton of Ophthalmology Times to discuss his poster "Travoprost Intraocular Implant Demonstrates Efficacy in Diverse Subpopulations of OAG and OHT Subjects," from the American Glaucoma Society meeting held in Huntington Beach
Fortifeye launches Eye Pressure and Neuro Cognitive Support supplement
February 29th 2024The supplement is specifically crafted to promote healthy intraocular pressure (IOP), nurturing the well-being of retinal ganglion cells, and sustain the health of the retinal nerve fiber layer while boosting memory and concentration.
AGS 2024: Leon Herndon, MD, President of AGS, previews the annual meeting
February 29th 2024Leon Herndon, MD, President of the American Glaucoma Society, sat down with David Hutton of Ophthalmology Times to discuss the AGS meeting held in Huntington Beach and what attendees can expect as well as new and exciting information to come from the meeting.
PulseSight Therapeutics launches to advance non-viral gene therapies for severe retinal diseases
February 28th 2024According to the company, its proprietary non-viral gene therapy platform with minimally invasive delivery technology is providing long lasting gene expression and favorable distribution in the retina.